The aim of this study is to evaluate the possible risks and the effectiveness of changing the basal insulin treatment of Type 2 diabetes patients to either Toujeo basal insulin, or another available standard of care basal insulin. This can be in combination with other non-insulin diabetes medication.
What does it involve?
Before taking part in the study a full medical history and examination must be taken to ensure that it is safe for you to take part. If eligible for the study you will be treated for 52 weeks with one of the following:
1. Toujeo (insulin glargine)
2. Available "standard of care" insulin
You will continue to take your other non-insulin glucose-lowering medication if appropriate.
The study consists of 6 clinic visits where we will take blood samples. You must fast for 8 hours before clinic visits.
Overall the duration of the study for each patient is approximately 53 weeks and comprises 3 periods: a 1-week screening period, a 26-week treatment period, and a 26-week extension period.
- Patients with Type 2 diabetes insufficiently controlled with current "standard of care" basal insulin therapy.
- Fasting plasma glucose >130 mg/dL
To refer potential participants or to request further information, please contact the research team:
Tel: 02380 475 258